Company news
Annovis Bio, Inc. (NYSE:ANVS) news
Every Annovis Bio, Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Annovis to Host Corporate Update Webinar on September 2, 2026
August 25, 2026
Annovis Provides Corporate Updates and Second Quarter 2026 Financial Results
August 14, 2026
Annovis Reaches Full Enrollment in Pivotal Phase 3 Trial of Buntanetap for Early Alzheimer’s Disease
July 7, 2026
Annovis Bio Regains NYSE Listing Compliance
May 26, 2026
Annovis Announces Pricing of $15.0 Million Public Offering of Common Stock and Accompanying Warrants
May 20, 2026
Annovis Announces Launch of Proposed Public Offering of Common Stock and Accompanying Warrants
May 19, 2026
Annovis Provides Corporate Updates and Reports First Quarter 2026 Financial Results
May 15, 2026
Annovis CEO to Present on Multi-Protein Model of Alzheimer's Disease at Fierce Biotech Week 2026
May 7, 2026
Annovis Publishes Phase 2/3 Alzheimer's Trial Results in Nature Portfolio
April 28, 2026
Annovis Closes $10 Million Offering, Extending Cash Runway Through Phase 3 Alzheimer's Disease 6-Month NDA Submission
April 10, 2026
Annovis Announces $10 Million Underwritten Offering of Common Stock and Accompanying Warrants
April 9, 2026
Annovis Secures U.S. Patent for Buntanetap in the Prevention and Treatment of Neurological Injuries Caused by Brain Infections
April 2, 2026
Annovis Publishes Historical Review of Buntanetap in The Scientist
March 31, 2026
Annovis Partners with NeuroRPM to Deploy AI-Powered Digital Biomarker Technology in Parkinson's Disease Study
March 19, 2026
Annovis Provides Corporate Updates and Reports Fiscal Year 2025 Financial Results
March 16, 2026
Annovis Announces Two Presentations at the AD/PD™ 2026 International Conference
March 3, 2026
Annovis Secures DSMB Approval to Advance Pivotal Phase 3 Trial of Buntanetap in Alzheimer’s Disease
February 12, 2026
Annovis Announces Open-Label Extension Study for Parkinson's Disease Patients
December 18, 2025
Annovis to Host Corporate Update Webinar on January 28, 2026
December 16, 2025
Annovis To Present at the 2025 Annual Meeting of the Parkinson Study Group
December 3, 2025
Annovis Announces Two Presentations at the CTAD 2025 Conference
November 24, 2025
Annovis Announces FDA Meeting to Discuss Parkinson's Disease Dementia Program; Reaffirms FDA Alignment on Pivotal Phase 3 Alzheimer's Dis...
November 18, 2025
Annovis Reports New Biomarker Data Linking Amyloid Co-Pathology to Accelerated Cognitive Decline in Parkinson's Patients
November 17, 2025
Annovis Provides Corporate Updates and Reports Third Quarter 2025 Financial Results
November 12, 2025
Annovis Achieves Significant Milestones and Sustains Strong Progress in Phase 3 Alzheimer’s Program
November 6, 2025
Annovis Announces $3.4 Million Registered Direct Offering of Common Stock Priced At-the-Market under the NYSE Rules
October 27, 2025
Annovis Announces Closing of $6 Million Registered Direct Offering of Common Stock
October 15, 2025
Annovis Announces $6 Million Registered Direct Offering of Common Stock
October 10, 2025
Annovis Announces Novel Biomarker Data in Alzheimer’s Patients Supporting Buntanetap’s Potential as a Disease-Modifying Treatment
October 9, 2025
Annovis Appoints Mark Guerin as Chief Financial Officer
September 25, 2025
Annovis Reports Peer-Reviewed Publication Highlighting Pharmacokinetics of Novel Crystal Buntanetap
September 16, 2025
Annovis to Present at the H.C. Wainwright 27th Annual Global Investment Conference
September 2, 2025
Annovis Provides Corporate Updates and Reports Second Quarter 2025 Financial Results
August 12, 2025
Annovis Completes Full Patent Transfer to Crystal Buntanetap
August 7, 2025
Annovis to Attend the AAIC 2025 with Four Poster Presentations
June 26, 2025
Annovis Announces NYSE Acceptance of Plan to Regain Listing Compliance
June 19, 2025
Annovis to Host Webinar and Live Q&A on June 24, 2025
June 5, 2025
Annovis Provides Corporate Updates and Reports First Quarter 2025 Financial Results
May 13, 2025
Annovis Bio Appoints Hui Liu as Director of Biostatistics
April 29, 2025
Annovis Bio, Inc. Receives Continued Listing Standard Notice From the NYSE
March 27, 2025
Annovis to Attend AD/PD™ 2025 with Extensive Scientific Program
March 25, 2025
Annovis Provides Corporate Updates and Reports Fourth Quarter and Fiscal Year 2024 Financial Results
March 21, 2025
Annovis Joins Experts at Drug Development Summit to Redefine Parkinson's Treatment
March 11, 2025
Annovis to Host Patients’ Live Forum on February 27, 2025
February 19, 2025